Immunosuppressants API Market to Grow with a CAGR of 8.25% through 2028
Rising prevalence of autoimmune diseases and increasing research
collaborations between pharmaceutical companies & research institutes is
expected to drive the Global Immunosuppressants API Market growth in the
forecast period, 2024-2028.
According to TechSci Research report, “Immunosuppressants
API Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2028”, the Global Immunosuppressants API Market stood
at USD 2.78 billion in 2022 and is anticipated to grow with a CAGR of 8.25% in
the forecast period, 2024-2028. The market is poised for substantial growth,
driven by emerging trends such as the increasing prevalence of autoimmune
diseases like Rheumatoid arthritis (RA), Psoriasis/psoriatic arthritis,
Multiple sclerosis, Inflammatory bowel disease, Addison's disease, and others. Additionally,
there is a surge in research and development activities within the
pharmaceutical sector, fostering numerous collaborations between pharmaceutical
companies and research institutes. Furthermore, significant investments in
clinical research and development by pharmaceutical companies contribute to the
market's growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Immunosuppressants API Market.”
The global immunosuppressants API market is
anticipated to witness substantial growth during the forecast period, primarily
driven by continuous technological advancements in tissue engineering. These
advancements are revolutionizing the field and paving the way for more
effective and targeted therapies. Additionally, the increasing incidence of
autoimmune disorders such as multiple sclerosis, alopecia areata, and arthritis
is significantly contributing to the market's growth. This can be attributed to
the growing awareness and diagnosis of these conditions, leading to a higher
demand for immunosuppressant API drugs.
Furthermore, the rise in organ transplants, including
liver and kidney transplants, on a global scale is expected to further propel
the market's expansion in the coming years. Organ transplantation has become a
crucial medical procedure for patients with end-stage organ failure, providing
them with a renewed lease on life. According to the United Network for Organ
Sharing, in 2021 alone, approximately 41,355 organ transplants were performed
worldwide. Kidney transplants accounted for 24,670 cases, followed by liver
transplants with 9,236 cases. Heart and lung transplants accounted for 3,817
and 2,524 cases, respectively. These numbers highlight the growing demand for
immunosuppressant drugs to prevent organ rejection and ensure the success of
these life-saving procedures.Moreover, it is worth mentioning that a
significant number of individuals are still awaiting a lifesaving organ
transplant. As of now, approximately 106,131 people are on the waiting list,
desperately hoping for a suitable organ donor. This underscores the urgent need
for continued advancements in immunosuppressant drugs and therapies to support
and improve the outcomes of organ transplantation. In addition to the factors
mentioned above, constant advancements in tissue engineering techniques are
pivotal in driving the overall development of the immunosuppressants API market.
These advancements enable the creation of more sophisticated and biocompatible
materials that can effectively modulate the immune response and promote better
tissue integration. As a result, patients can experience improved outcomes and
enhanced quality of life.
Furthermore, the growing geriatric population, with
its higher susceptibility to autoimmune diseases, adds to the market's growth
potential. Age-related decline in immune function and the higher incidence of
chronic conditions contribute to the increased demand for immunosuppressants.
Additionally, the rapid growth of the biopharmaceuticals sector, with its focus
on innovative drug development and precision medicine, further supports the
expansion of the immunosuppressants API market.
Despite these positive growth drivers, it is important
to acknowledge certain challenges that may impede the market's progress in the
coming years. High costs associated with API production and limited
availability of organ donors remain significant obstacles. Addressing these
challenges will be crucial for the sustained growth and accessibility of
immunosuppressant drugs worldwide.The global immunosuppressants API market is
poised for remarkable growth, fueled by technological advancements, the
increasing prevalence of autoimmune diseases, rising organ transplant
procedures, and the expanding biopharmaceuticals sector. By leveraging these
opportunities and addressing the associated challenges, the market can continue
to evolve and contribute to improved patient outcomes and well-being.
The Global Immunosuppressants API Market is segmented
method, application, type, product, APIs, end user, regional distribution, and
company.
Based on end user, biotechnology and biopharmaceutical
companies are dominating the global Immunosuppressants API market primarily due
to their robust research and development capabilities, their capacity for
large-scale production, and their relentless pursuit of innovation. These
companies heavily invest in cutting-edge technologies, such as genetic
engineering and bioinformatics, to continuously develop and refine new
immunosuppressive drugs. Through strategic collaborations and partnerships,
these companies also establish a global presence, allowing them to access wider
markets and cater to the growing demand for effective immunosuppressants.
Moreover, the significance of these companies extends
beyond their contributions to the pharmaceutical industry. Their focus on
developing immunosuppressive drugs plays a crucial role in the treatment of
autoimmune disorders and organ transplant procedures. By constantly pushing the
boundaries of scientific advancements, these companies help improve the quality
of life for patients worldwide, offering hope and better outcomes in the face
of challenging medical conditions. Biotechnology and biopharmaceutical
companies are at the forefront of the global Immunosuppressants API market,
driven by their research capabilities, production capacity, and dedication to
advancing medical science. Their relentless pursuit of innovation and
commitment to improving patient care make them key players in addressing the
complex challenges of autoimmune disorders and organ transplant procedures.
Based on region, North America segment is expected to
grow during the forecast period. North America is currently at the
forefront of the global Immunosuppressants API (Active Pharmaceutical
Ingredient) market. This can be attributed to its advanced healthcare
infrastructure, which ensures quality patient care and access to cutting-edge
medical treatments. The region also boasts a robust pharmaceutical industry,
with leading companies investing heavily in research and development to drive
innovation in immunosuppressant therapies.
Additionally, North America has a relatively high
prevalence of autoimmune diseases, which further fuels the demand for
immunosuppressant medications. The region's healthcare system is well-equipped
to diagnose and treat these conditions, with a strong emphasis on organ
transplants. Heightened awareness about the benefits of organ transplantation,
coupled with a well-established insurance structure that often covers these
procedures, contributes to the overall growth of the market. Furthermore, North
America benefits from the presence of key market players who actively
contribute to the development and commercialization of immunosuppressant APIs.
These companies collaborate with research institutions and healthcare providers
to drive continuous research and development activities, ensuring that the region
remains at the forefront of innovation in this field. All these factors
combined contribute to North America's dominance in the global
Immunosuppressants API market, making it a key player in shaping the future of
immunosuppressant therapies worldwide.
Major companies operating in
Global Immunosuppressants API Market are:
- Biocon
Ltd.
- NATCO
Pharma Limited
- Triveni
Interchem Private Limited
- Concord
Biotech Ltd.
- RPG
Life Sciences Limited
- Jiangsu
Jiuyang Bio-Pharmaceutical Co. Ltd.
- Chunghwa
Chemical Synthesis & Biotech Co. Ltd.
- AbbVie
Inc.
- Pfizer
Inc.
- Zhejiang
Hisun Pharmaceutical Co. Ltd.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The future of the global Immunosuppressants API (Active
Pharmaceutical Ingredients) market looks promising, underpinned by the
increasing prevalence of autoimmune diseases, advanced organ transplantation
procedures, and a growing geriatric population susceptible to chronic
conditions. Technological advancements in pharmaceutical research are expected
to unveil more effective and targeted Immunosuppressant APIs, driving the
growth of the market. However, the market also faces potential challenges such
as stringent regulation, the high cost of drugs, and side effects associated
with long-term use of Immunosuppressants. These factors will shape the dynamics
of the Immunosuppressants API market in the coming years.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management consulting
firm.
“Immunosuppressants API Market Segmented By Method
(Synthetic Chemistry, Peptide chemistry, Fermentation, Chromatographic
purification), By Application (Autoimmune Disease, Organ Transplant), By Type
(Corticosteroids, Janus Kinase Inhibitor, Calcineurin Inhibitors, mTOR
Inhibitor, Others), By Product (Tablets, Capsules, Liquids, Injections), By
APIs (Tacrolimus, Sirolimus, Everolimus, Mycophenolate Mofetil, Mycophenolate
Sodium), By End User (Biotechnology & Biopharmaceutical Companies, CMOs,
CROs, CDMOs, Others), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Immunosuppressants API Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Immunosuppressants API Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com